400
Participants
Start Date
May 30, 2021
Primary Completion Date
July 19, 2021
Study Completion Date
December 30, 2021
SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
Saline placebo
0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
Espinas Palace Hotel, Tehran
Lead Sponsor
Vaxine Pty Ltd
INDUSTRY
Cinnagen
INDUSTRY